Genor Biopharma Holdings Limited

SEHK:6998 Stock Report

Market Cap: HK$857.4m

Genor Biopharma Holdings Management

Management criteria checks 3/4

Genor Biopharma Holdings' CEO is Feng Guo, appointed in Apr 2020, has a tenure of 4.67 years. total yearly compensation is CN¥24.29M, comprised of 18.5% salary and 81.5% bonuses, including company stock and options. directly owns 1.34% of the company’s shares, worth HK$11.53M. The average tenure of the management team and the board of directors is 4.5 years and 3 years respectively.

Key information

Feng Guo

Chief executive officer

CN¥24.3m

Total compensation

CEO salary percentage18.5%
CEO tenure4.7yrs
CEO ownership1.3%
Management average tenure4.5yrs
Board average tenure3yrs

Recent management updates

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 20
Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 20
Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

May 29
Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

Dec 29
We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Dec 21
We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Sep 05
Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Dec 03
We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Aug 28
Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

May 10
Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Feng Guo's remuneration changed compared to Genor Biopharma Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥526m

Mar 31 2024n/an/a

-CN¥600m

Dec 31 2023CN¥24mCN¥5m

-CN¥674m

Sep 30 2023n/an/a

-CN¥637m

Jun 30 2023n/an/a

-CN¥599m

Mar 31 2023n/an/a

-CN¥665m

Dec 31 2022CN¥32mCN¥5m

-CN¥730m

Sep 30 2022n/an/a

-CN¥800m

Jun 30 2022n/an/a

-CN¥870m

Mar 31 2022n/an/a

-CN¥868m

Dec 31 2021CN¥41mCN¥5m

-CN¥865m

Compensation vs Market: Feng's total compensation ($USD3.33M) is above average for companies of similar size in the Hong Kong market ($USD230.88K).

Compensation vs Earnings: Feng's compensation has been consistent with company performance over the past year.

CEO

Feng Guo (54 yo)

4.7yrs

Tenure

CN¥24,285,000

Compensation

Dr. Feng Guo Ph D., served as Chairman of the Board for Genor BioPharma Co., Ltd. since November 2021 until September 12, 2024.He served as Chairman at Genor Biopharma Holdings Limited since November 02,...

Leadership Team

NamePositionTenureCompensationOwnership
Feng Guo
Chief Executive Officer4.7yrsCN¥24.29m1.34%
HK$ 11.5m
Chengyi Weng
CFO, Company Secretary & Executive Directorno datano data0.072%
HK$ 618.4k
Qibin Liang
Chief Technology Officer3.2yrsno datano data
Xiaojing Zhu
Vice President of Compliance & Administrationno datano datano data
Tong Li
Chief Medical Officer4.3yrsno datano data
Tak Wai Ip
Company Secretary2.5yrsno datano data
Jun Lin
Vice President of Quality Analysis4.9yrsno datano data
Qingtang Duan
General Manager of Yuxi Genor5.3yrsno datano data

4.5yrs

Average Tenure

54yo

Average Age

Experienced Management: 6998's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chengyi Weng
CFO, Company Secretary & Executive Directorless than a yearno data0.072%
HK$ 618.4k
David J. Kerr
Member of Scientific Advisory Board3yrsno datano data
Leonard B. Saltz
Member of Scientific Advisory Board3yrsno datano data
Wen Chen
Independent Non-Executive Director4.5yrsCN¥420.00kno data
Alex A. Adjei
Member of Scientific Advisory Board3yrsno datano data
Edwin Fung
Independent Non-Executive Director4.5yrsCN¥420.00kno data
Dong Lyu
Non Executive Director3.1yrsno datano data
Zhijian Chen
Chairman of Scientific Advisory Board3.6yrsno datano data
Yangxin Fu
Member of Scientific Advisory Board3yrsno datano data
John F. Seymour
Member of Scientific Advisory Board3yrsno datano data
John R. Zalcberg
Member of Scientific Advisory Board3yrsno datano data
Yi Liu
Non-Executive Director2.4yrsno datano data

3.0yrs

Average Tenure

56yo

Average Age

Experienced Board: 6998's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 21:16
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genor Biopharma Holdings Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyi ChenGoldman Sachs
Yue-Kwong LuiJefferies LLC
Ling WangJ.P. Morgan